{'fraction_non_alphanumeric': 0.03270440251572327, 'fraction_numerical': 0.00440251572327044, 'mean_word_length': 5.21484375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Within-person, among-finger variability of capillary blood glucose measurements.

Many diabetic patients use home-use glucose monitors for glycemic control (1)(2). Ideally, in studies comparing and assessing the variability among monitors, testing should be done with the same type of sample used by patients, i.e., capillary whole blood. Simultaneous evaluation of multiple monitors requires more sample than can effectively be collected by lancing a single finger one or more times. Samples may therefore need to be collected from multiple fingers, and if so, the among-finger variability will need to be quantified before a study of among-monitor variability can be conducted. To our knowledge, no studies have been published that report among-finger variability in blood glucose measurements within an individual patient. Because evaluation of multiple monitors using multiple samples from an individual also assumes that the within-person blood glucose will be stable for the duration of the testing period, we tested, in a pilot study using a HemoCue 201 point-of-care glucose analyzer, the assumptions that the within-person, among-finger variability (hereafter referred to as “among-finger” variability) is negligible and that the within-person blood glucose is stable over a period of 35 min.

The Institutional Review Boards at the CDC and at Research Triangle Institute (where the study was conducted) approved the protocol. Free-living, community-dwelling people recruited from the Raleigh-Durham-Chapel Hill metropolitan area of North Carolina gave informed consent. Diabetic …